Deerfield Management Company, L.P. (Series C) Tg Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.04 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 14, 2024	BUY	$17.21 - $25.28 $197,536 - $290,163	11,478 New	11,478 $268,000
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $10 Million - $28.5 Million	2,677,500 New	2,677,500 $11.4 Million

Others Institutions Holding TGTX

# of Institutions

371

Shares Held

85.9M

Call Options Held

3.64M

Put Options Held

2.59M

Vanguard Group Inc Valley Forge, PA

15.6M
Shares

$479 Million
0.01% of portfolio
Black Rock Inc. New York, NY

11.4M
Shares

$350 Million
0.0% of portfolio
State Street Corp Boston, MA

9.2M
Shares

$283 Million
0.01% of portfolio
Geode Capital Management, LLC Boston, MA

3.19M
Shares

$98.1 Million
0.01% of portfolio
Pictet Asset Management Holding Sa Carouge, V8

2.79M
Shares

$85.8 Million
0.09% of portfolio

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.46B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account